carbamates has been researched along with brecanavir in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, HL; Danger, D; Furfine, ES; Hanlon, MH; Kaldor, IW; Miller, JF; Porter, DJ; Samano, VA; Shu, AY; Spaltenstein, A | 1 |
| Anderson, MT; Fernandez, P; Ford, SL; Johnson, MA; Murray, SC; Reddy, YS; Stein, DS | 1 |
| Anderson, MT; Ford, SL; Johnson, MA; Murray, SC; Ng-Cashin, J; Reddy, YS | 1 |
| Garges, HP; Lalezari, JP; Tomkins, SA; Ward, DJ | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Baughman, TM; Johns, BA; Temelkoff, DP; Velthuisen, EJ; Weatherhead, JG | 1 |
3 trial(s) available for carbamates and brecanavir
| Article | Year |
|---|---|
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Benzodioxoles; Capsules; Carbamates; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Flatulence; Gels; Half-Life; Headache; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nausea; Ritonavir | 2006 |
Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.
Topics: Adult; Area Under Curve; Benzodioxoles; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Safety | 2007 |
Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Benzodioxoles; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome | 2007 |
4 other study(ies) available for carbamates and brecanavir
| Article | Year |
|---|---|
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Topics: Amino Acid Substitution; Binding, Competitive; Carbamates; Chromatography, Affinity; Chromatography, Gel; Dextrans; Dimerization; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Protein Binding; Saquinavir; Spectrometry, Fluorescence; Substrate Specificity; Sulfonamides | 2004 |
Brecanavir's hopes dashed.
Topics: Anti-HIV Agents; Benzodioxoles; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase II as Topic; Drug Approval; Humans | 2007 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs.
Topics: Administration, Intravenous; Animals; Area Under Curve; Benzodioxoles; Carbamates; Deuterium; Hepatocytes; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Models, Chemical; Molecular Structure; Rats | 2013 |